In practice, vaccines should induce lasting and efficacious T cell immunity without promoting deleterious pathological consequences. To accomplish this goal we immunized mice with ovalbumin peptide, polyinosinic-polycytidylic and anti-CD137. Vaccinated mice retained a massive functional CD8 T cell memory pool in lymphoid and non-lymphoid tissues for >1 year. The memory T cells clonally expanded, produced substantial amounts of IFNc, and responded vigorously to vesicular stomatitis virus infection. To understand how the vaccine might function, we showed that the antigen-specific T cells must bear CD137 in order for optimal priming to occur. Thus, anti-CD137 agonist mAb directly stimulated peptide-specific CD8 T cells and conditioned them to survive. In contrast, CD137-deficient CD8 T cells did not survive despite CD137 expression by antigen presenting cells. Taken together, the data indicate that CD137 and adjuvant combined therapy is an efficacious vaccine strategy for immunization with non-replicating inert antigen.
Introduction
Memory T cell subsets are detected in distinct locations in the body (1) , with central memory cells restricted to lymphoid organs and effector memory cells dispersed throughout the non-lymphoid tissues such as the liver and lung (2, 3) . The peripheral location and potent response of the effector memory cells allows them to be on the front line of defense after re-infection (4) . An optimal vaccination strategy produces both subsets that are long-lasting populations and capable of functioning in aged animals. It has been demonstrated that as mice age the T cell compartment acquires a reduced ability to mount productive immune responses (5, 6) , lending to the frustration of producing vaccines that provide protection years after immunization.
Co-stimulation of T cells along with presentation of antigen in the context of MHC is required to generate a productive immune response. The compilation of data regarding co-stimulation suggest that co-stimulatory receptors share overlapping and unique functions, as well as distinct temporal and cell-type-specific expression patterns (7) . This diversity provides multiple targets for immune conditioning through the exploitation of co-stimulatory signals during vaccination. Enforced co-stimulation can boost T cell survival (8) , as well as enhance effector function of T cells during the priming phase of the immune response (9, 10) .
As an example, CD137 is a member of the tumor necrosis factor receptor family and has been shown to augment CD4 and CD8 T cell responses (11) (12) (13) (14) (15) (16) . CD137 is rapidly expressed on 24-h peptide stimulated CD4 and CD8 T cells (17) , and at even earlier time points after in vivo superantigen stimulation (14) . Importantly, CD137 co-stimulation substantially enhances CD8 T cell effector responses (7) . This has been demonstrated in viral infection models of influenza (18) and lymphocytic choriomeningitis virus (19) . Also, CD137 costimulation has been reported to expand populations of T cells specific to non-dominant viral epitopes (20) . Lastly, therapeutic use of agonist anti-CD137 mAbs as shown to induce elimination of established tumors (13, 21) .
We combined a therapeutic anti-CD137 mAb with polyinosinic-polycytidylic (PIC) to formulate a peptide-based vaccine. Peptide-specific CD8 T cells were detected in great abundance over a year later and, importantly, continued to possess potent Tc1-type effector function. To examine the mechanism of CD137 co-stimulation, we developed an in vivo model where the responding Tcells either expressed or lacked CD137. This is crucial since many cell populations besides activated T cells express CD137 (22) (23) (24) (25) . The data demonstrate that CD137-expressing T cells, as opposed to nonexpressing T cells, underwent substantial antigen-specific clonal expansion after triggering CD137 with the therapeutic mAb. Taken together, CD137-enforced co-stimulation therapy may be a useful tool for developing vaccines toward nonreplicating inert antigen, without the need for live-attenuated or heat-killed pathogens.
Methods
Mice, reagents, mAbs and injections C57BL/6, C57BL/6 CD45.1 and C57BL/6 Thy1.1 mice were purchased from the National Cancer Institute (Frederick, MD, USA) or Jackson Laboratory (Bar Harbor, ME, USA). The C57BL/6 CD45.1 + OTI transgenc mice (26) were kindly provided by Zihai Li (University of Connecticut Health Center, Farmington, CT, USA), and the C57BL/6 CD137 ÿ/ÿ (27) and C57BL/6 OTI CD137 ÿ/ÿ mice were bred in our laboratories. All mice were maintained in accordance with federal guidelines.
Adoptive transfers were performed by intravenous (i.v.) injection and all immunizations were through the intraperitoneal route. A total of 1 mg of ovalbumin peptide (OVA) (Sigma, St Louis, MO, USA) was injected in sterile balanced salts solution (BSS). The agonist anti-CD137 mAb was purified from 3H3 hybridoma culture supernatant by protein-G agarose column (Invitrogen, Grand Island, NY, USA) and was injected at a dose range between 25 and 100 lg based on batch-tobatch potency determined by T cell clonal expansion in a titration assay (13) . A rat IgG was used as the control (Sigma), and was given at an equivalent dose. PIC was administered at 150 lg and LPS at 40-60 lg (both from Sigma). SIINFEKL peptide was produced by Invitrogen and injected at 100 lg for T cell priming or at 200 lg for memory T cell recall in congenic recipients (as noted in the figure legends).
Cell processing, staining and flow cytometry
Blood was collected by tail bleeding into 10 U ml ÿ1 heparinized BSS, followed by lysis of RBCs using ammonium chloride. For lung and liver analyses, mice were anesthetized with ketamine/xylazine and then perfused with heparinized PBS solution and tissues processed for lymphocyte removal as previously described (4) . Briefly, the spleen and liver were crushed through nylon mesh cell strainers (Falcon; BD Biosciences, San Diego, CA, USA) and RBCs lysed with ammonium chloride. Liver hepatocytes were removed using a 35% percoll gradient and lung tissue digested in a 150-U ml ÿ1 collagenase solution followed by lymphocyte collection at the interface of a 44%/67% percoll gradient. Cells were washed with BSS, counted using a Z1 particle counter (Beckman Coulter, Miami, FL, USA) and placed into staining buffer (BSS, 3% FBS, 0.1% sodium azide).
Non-specific binding was blocked using 5% heat-inactivated normal mouse serum, culture supernatant from the 2.4.G.2 hybridoma (28) and 10 lg ml ÿ1 human c globulin (Sigma). The incubation with primary mAbs was for~30 min on ice. Anti-CD8, -CD11a, -CD45.1, -CD45.2, -CD90.1 and -CD90.2 mAbs were purchased from either BD PharMingen (San Diego, CA, USA) or eBiosciences (San Diego, CA, USA) and were conjugated to FITC, PE, allophycocyanin, peridinin chlorophyll protein or PE-Cy7. For tetramer staining, SIINFEKL-tetramer and anti-CD8 mAb were incubated for 1.5 h at room temperature prior to primary antibodies.
For intracellular cytokine staining, between 1 3 10 6 and 3 3 10 6 splenocytes were cultured in U-bottom 96-well plates (Falcon) for 5 h at 37°C and 5% CO 2 with 1 lg brefeldin A (Calbiochem). Cultures were placed in complete tumor media (MEM with amino acids, salts, antibiotics and FBS) with either nothing or 5 lg ml ÿ1 SIINFEKL peptide (Invitrogen). Cells were then stained with anti-CD8-allophycocyanin (eBioscience) or anti-CD45.2-Cy5, fixed with 2% PFA BSS and permeabilized with 0.25% saponin (Sigma) in staining buffer. The cells were then incubated for 15 min at room temperature followed by 30 min on ice with anti-IFNc-PE, anti-IL-4-PE (data not shown) or an isotype control (eBioscience).
Cells were analyzed on a FACSCalibur (BD Biosciences, Mountain View, CA, USA) or an LSR-II (Becton Dickinson) and data analysis was completed using CELLQUEST (BD Biosciences) or FlowJo (Tree Star, San Carlos, CA, USA) software.
Cell proliferation
To measure in vivo clonal expansion, 1.5 3 10 6 to 3.5 3 10 6 total cells from mice immunized previously were adoptively transferred into CD45.1 congenic recipients. In some instances, the splenocytes were enriched for lymphocytes by passing over a nylon wool column (29) . The next day, 200 lg of SIINFEKL peptide was given intra-peritoneally (i.p.) and spleens of the recipients were analyzed 6-7 days later for the percent CD45.2 + CD8 + SIINFEKL-tetramer + population. Also, without adoptive transfer, memory cells were directly challenged with 200 lg SIINFEKL. Mice were bled before and after recall immunization to determine the percent CD8 + CD11a hi SIINFEKL-tetramer + cells. Only mice that generated a priming response were analyzed.
Proliferation of memory cells was also tested using infection by recombinant vesicular stomatitis virus expressing ovalbumin peptide (VSV-OVA) (30) . Mice immunized either 2 or 17 months prior, or age-matched normal controls, were intravenously injected with 10 5 plaque-forming units (PFUs) and monitored for the percent of CD8 + T cells that were CD11a hi SIINFEKL-tetramer + post-infection.
Results

CD137 and adjuvant combined therapy generates long-lived CD8 + memory T cells
Optimal adaptive immune responses are dependent on longterm surviving T cells that possess the ability to develop into functional memory cells. To test the longevity potential of CD8 + T cells, mice were immunized with various combinations of OVA, anti-CD137 mAb, control IgG, LPS and PIC or left as unimmunized controls and then analyzed after priming through over 1 year later. This approach permitted analysis of endogenous T cells thereby avoiding complications of analyzing transferred T cells. Table 1 lists the vaccine treatments, the percent of endogenous CD8 + T cells that were SIINFEKL-tetramer + during the priming phase (at 6-7 days) followed by the percent and number remaining at 10-29 months post-immunization.
As shown in Table 1 , no immunization or immunization with OVA alone led to very little priming or memory. Even inclusion of PIC adjuvant or anti-CD137 was not sufficient to consistently induce lasting memory, although in some cases substantial priming was evident ( Table 1 , lines 9 and 10). However, combining PIC with anti-CD137 induced lasting T cell survival in response to OVA only when priming was excellent ( Table 1 , compare lines 11-13 with 14-18). This result is magnified when analyzing absolute numbers especially considering that in unimmunized mice the specific cells are practically undetectable. This was also the case when analyzing adjuvant and anti-CD137 immunized mice at >2 years (Table 1, 
lines 21-30).
A second test of the potency of this immunization protocol was a booster given a week after the primary immunization. An impressive >8-fold increase in number was detected with a single boost compared with the primary immunization alone (Table 1, lines 19 and 20) . Also, a double booster of anti-CD137 and OVA significantly enhanced memory (Table 1, line  30 ). These data show that the combination of anti-CD137 and PIC synergistically induced lasting CD8 T cell memory in response to inert antigen.
The CD8
+ T cell memory pool disperses into peripheral tissues, acquire a survival advantage, produce effector cytokines and clonally expand An important feature of memory T cells is their ability to disperse into peripheral tissues. Therefore, we compared the frequency of specific T cells from spleen, lung and liver from 2-month immunized mice with 15-16 month (Fig. 1a) . The data make two important points with the first being that our immunization protocol robustly induces migration of memory T cells into lung and liver. Secondly, it is clear that as the mice aged the proportion of CD11a hi memory T cells increased as compared with the decline of CD11a lo CD8 T cells (compare top panels with bottom). To quantify changes within the OVAspecific population, we contrasted the priming phase and endpoint for 2-3 month versus >11-month immunized mice (Fig. 1b) . We compared immunized mice that displayed comparable levels of excellent priming (Fig. 1b, left panel) , and found that at 2-3 months the percent of the specific population was less than at >11 months, which was substantiated by absolute numbers (Fig. 1b, middle and right panels). These data suggest that a single immunization through CD137 and PIC, endows the SIINFEKL-specific T cells with an escalating survival advantage.
Survival of memory T cells without function may actually be detrimental to the host since they would take up space and deplete resources without performing a protective role. Therefore, we tested if the memory cells were capable of producing IFNc in a 5-h re-stimulation assay followed by intracellular cytokine staining (Fig. 1c) . Bulk splenocytes from unimmunized mice, mice immunized 2 or 16 months prior with OVA/anti-CD137/PIC were placed separately into culture and re-stimulated with nothing (media alone) or with SIINFEKL peptide. Since re-stimulation of T cells induces TCR downregulation thereby preventing TCR detection with tetramers, we determined the percent of tetramer-positive T cells before the 5-h culture (the data in parentheses), which is compared with the percent CD8 IFNc double-positive cells after stimulation (the data above the parentheses). No IL-4 was produced in response to SIINFEKL (data not shown). In contrast, CD8 T cells taken from the 2-or 16-month immunized mice produced substantial amounts of IFNc (Fig. 1c) . By inference, nearly half of the 6.5% tetramer cells from the 16-month memory population made IFNc (Fig. 1c, bottom panel) .
To measure memory cell clonal expansion, we used young congenic recipients, so that T cell proliferation was tested without the complication of inefficient APC function in old mice (31) . Following adoptive transfer into CD45.1 + mice, a single dose of SIINFEKL peptide alone was given, and 6-7 days later, spleens were examined for changes in the percent of CD8 + SIINFEKL-tetramer + cells (Fig. 2a) . SIINFEKL was used to stringently permit analysis of only the memory cells. For example, inclusion of adjuvants and/or co-stimulation would induce naive T cells and therefore create either help or competition for the target memory cells. To determine the starting population, gated CD8 T cells that were CD11a hi SIINFEKL-tetramer + was determined before recall at the time of transfer (left panels), and compared with the percent gated CD8 T cells bearing CD45.2 SIINFEKL-tetramer after recall (right panels) (Fig. 2b) . The fold induction of clonal expansion was between 3.8 and 6.5 in this study (Fig. 2c) . We also tested the ability of the memory cells to be recalled in intact mice without any adoptive transfer in three separate experiments. In experiment one, mice immunized 7 weeks prior with OVA/IgG/PIC or OVA/anti-CD137/PIC or unimmunized controls were bled on the day of recall to establish the basal level of SIINFEKL-specific T cells (Fig. 3a, day 0) . The unimmunized mice did not generate a detectable immune response, but in mice primed with anti-CD137 mAb, the percent of CD8 + SIINFEKL-tetramer + cells was more than doubled in blood by day 7 post-recall (Fig. 3a) . In contrast, the mice primed without anti-CD137 co-stimulation had no significant increase in SIINFEKL-tetramer + cells following recall, although there was a detectable population both at time zero and on all the days the mice were analyzed. Therefore, these experiments showed that the memory cells were able to clonally expand in response to signal 1.
Since in the previous experiments a detectable primary response in the normal control animals was not generated, we used a different experimental system that would allow us to compare a secondary response with a detectable primary response. To accomplish this goal, mice were immunized with OVA/anti-CD137/PIC 2 months (Fig. 3b) or 17 months (Fig. 3c ) earlier and compared with age-matched unimmunized mice in response to infection with 10 5 PFU VSV-OVA (30) . The primary response by the CD8 + SIINFEKL-tetramer + cells was detectable but the T cells in the memory mice generated a faster response and a higher magnitude of CD8 + SIINFEKLtetramer + cells. These data show the expected enhanced kinetics of memory cell responses and support the conclusion that this immunization protocol may be efficacious for vaccination against pathogens.
Testing the direct effect of CD137 co-stimulation on specific T cells
Unlike other co-stimulators, CD137 is expressed on many cell types thereby complicating the precise target of anti-CD137 mAbs. Our goal was to examine the direct effects of CD137 ligation on T cells during priming to OVA. C57BL/6 (wt) and CD137 ÿ/ÿ mice were injected with OVA, anti-CD137 mAb and PIC, and blood was taken on days 3 and 5, and the spleens were harvested 7 days post-injection to analyze the percent of CD8 + T cells being CD11a hi SIINFEKL-tetramer + . There were no detectable SIINFEKL-tetramer + cells 3 days after immunization in either the wt or CD137 ÿ/ÿ mice (Fig. 4b) . By day 5 post-immunization, SIINFEKL-tetramer + populations increased in both types of mice. By day 7 the SIINFEKLtetramer + cells in the spleens of CD137 ÿ/ÿ mice had not increased from day 5 levels, but had increased by almost 3-fold in the wt mice.
To directly test whether CD137 expression by T cells was required, wt OTI cells or OTI CD137
ÿ/ÿ cells were separately transferred into the recipient congenic Thy1.1 wt mice and a day later immunized with SIINFEKL, anti-CD137 mAb and PIC. On day 5 after immunization, spleen or lymph node cells were analyzed for the absolute number of Thy1.1 ÿ OTI cells (Fig. 4a, top panel) . The number of CD8 + T cells able to bind SIINFEKL-tetramer from peripheral lymph node was much greater compared with identically treated CD137 ÿ/ÿ OTI recipients. In a separate experiment we analyzed spleen cells using an identical experimental approach and found similar results (Fig. 4a, bottom panel) . Importantly, the CD137 ÿ/ÿ OTI cells did expand on day 2 (data not shown), but clearly did not survive. Therefore, these data suggest that CD137 expression by peptide-specific T cells is necessary for optimal responsiveness to the anti-CD137 agonist mAb.
Discussion
To avoid the classical problem of non-specific inflammatory responses such as those derived from heat-killed or liveattenuated pathogens, a vaccine formulation comprised of PIC, anti-CD137 therapeutic mAb and an inert non-replicating antigen was tested. The results show that CD8 memory T cells were capable of robust effector function and were detected over 1 year later.
In order for CD137 immunotherapy to be efficacious for vaccine development, the induction of lasting memory T cells with appropriate effector function is essential (7) . In this context, survival of T cells is not sufficient for memory since survival coupled to unresponsiveness is likely to be detrimental. For example, surviving T cells unable to be recalled would tap the body for valuable resources and occupy space that could be used by productive memory cells. Thus, we set out to stringently test whether anti-CD137 immunotherapy would be efficacious in generating lasting, functional memory that would be retained in aged mice.
Our data are comprehensively summarized in Table 1 showing various treatments, followed by measurements of primary responses, frequency and numbers of surviving peptide-specific T cells. Several important ideas are revealed by this data with one being that the combination of PIC with CD137 co-stimulation synergistically induced lasting survival of memory CD8 T cells (Table 1 ). The mechanism of this synergism is currently unknown, but perhaps it is dependent on one of these stimuli regulating the other. For example, PIC or other adjuvants may induce and maintain CD137 expression on the specific T cell allowing for more binding time with the antibody. On the other hand, it is possible that CD137 stimulation induces TLR3 expression on the stimulated T cells. This notion is consistent with previously published data showing that PIC can induce T cell survival (32) .
A second observation is that the magnitude of priming did not always determine the magnitude of memory. In fact, the booster immunization did not enhance priming compared with no booster, but boosting substantially enhanced the frequency and absolute number of memory cells by several fold (Table 1 , compare lines 11-13 with [14] [15] . This is an example of how clonal expansion or proliferation can be separated from survival, as we have suggested in the past (33) . Nonetheless, excellent priming after anti-CD137/PIC seemed to dictate the robustness of memory (Table 1 , compare lines 11-13 with 14-18).
Ultimately, the surviving cells were dispersed throughout lymphoid and non-lymphoid tissues (Fig. 1) . This is likely to be important for acquisition of functional memory since infection may be localized to a specific peripheral organ (1) . Additionally, we found suggestive evidence that the frequency of surviving cells appeared to increase over time after immunization (Fig. 1b) . A possible explanation for the continued increase in frequency of specific T cells may be derived from the poor production of naive T cells from the thymii in aged mice as indicated by the reduction of CD11a low-expressing cells (Fig. 1a) . Nevertheless, the absolute number of SIINFEKLspecific memory T cells also increased, suggesting additional processes like enhanced competition by surviving memory for resources and space (Fig. 1b) . Ultimately, these data need to be extrapolated into other systems in order to form a broad conclusion regarding escalation of numbers of memory cells over time.
Finally, we showed that the lasting memory cells were capable of potent recall responses. The fact that aged APCs may not be as functional as APCs from younger mice was examined using a transfer assay (31) . The data show pronounced clonal expansion in response to SIINFEKL recall demonstrating that the lasting memory cells were very capable of clonal expansion (Fig. 2) . Further testing showed that even recall in response to SIINFEKL peptide alone without any transfer induced expansion (Fig. 3a) , but recall responsiveness to VSV-OVA infection was massive ( Fig. 3b  and c) . Specifically, the former case may be more a stringent test but less likely to be physiological, whereas infection perhaps best mimics natural circumstances.
As a measurement of efficacious effector function we chose to examine IFNc production in response to recall with SIINFEKL peptide. This is an important parameter since clonal expansion without acquisition of effector function would likely hamper vaccination efforts against pathogens. Peptidespecific T cells taken from the 16-month immunized mice produced substantial amounts of IFNc after in vitro recall (Fig. 1c) . We estimated that over half of the SIINFEKL-tetramer + cells synthesized IFNc after in vitro recall, and this data were consistent with IFNc data from other mice immunized in the same fashion as well as the recipient mice shown in Fig. 2 (data not  shown) . Collectively, these results support our conclusion that enforcing stimulation of CD137 and TLR3 induces lasting functional memory CD8 T cells after only a single immunization with inert antigen.
To better understand how the immunizing regimen was working, we examined the initiation of the response. During the primary response the peptide-specific T cells in the CD137 ÿ/ÿ mice exhibited weakened clonal expansion compared with T cells in wt mice (Fig. 4) . One interpretation of this data suggests that non-T cells in the CD137 ÿ/ÿ mice lack CD137 and therefore could not provide all the appropriate signals from optimal expansion. This is particularly relevant since many different cell types like DCs, FDCs and NK cells can directly respond to CD137 stimulation (22) (23) (24) (25) . Alternatively, stimulation of CD137 on the peptide-specific T cells may be essential for this response. To test this idea, OTI and OTI CD137 ÿ/ÿ T cells were transferred into wt recipient mice and then immunized. The CD137-expressing OTI T cells accumulated to a much greater degree compared with the nonexpressing cells (Fig. 4a) . Therefore, potential to express CD137 by T cells led to a greatly enhanced response and this data extend previous observations demonstrating that CD137 co-stimulation is crucial for the late primary response of peptide-specific CD8 T cells after influenza infection (17, 18, 34, 35) .
The mechanism of how the memory pool is maintained and how effector function is preserved is unknown, but perhaps direct CD137 signaling by the anti-CD137 therapeutic mAb conditions the target cells to acquire a unique genetic program pre-disposed to survival and IFNc synthesis. For example, CD137 may induce expression of IL-7R or IL-15R, thereby providing a mechanism for maintenance of CD8 memory T cells (36, 37) .
Our study demonstrates that under the appropriate conditions, anti-CD137 therapeutic mAb potently generates functional memory cells. This data may provide new insight into better vaccine practices, and perhaps more effective approaches for immunizing aged populations.
